You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
凱萊英(002821.SZ):擬投資30億元在上海奉賢建生物藥CDMO研發及商業化生產基地

格隆匯3月4日丨凱萊英(002821.SZ)公佈,為推動公司整體產業發展的戰略佈局,進一步提升公司新興業務板塊的服務能力,公司與上海市工業綜合開發區有限公司於2022年3月4日簽署投資協議書,公司投資新設的全資子公司,擬以自有或自籌資金30億元人民幣在上海奉賢投資建設生物藥CDMO研發及商業化生產基地。該事項已於2022年3月4日經公司第四屆董事會第二十二次會議審議通過,尚需提交公司股東大會審議,股東大會召開時間另行通知。

當前全球創新藥產業蓬勃發展,疊加醫藥外包服務專業化分工的持續深入,醫藥CDMO行業呈現出更大的發展機遇,尤其近年來以抗體偶聯藥物(ADC)、新型抗體藥物等為代表的生物藥,已經過多年快速發展邁向收穫期。公司堅持以技術革新作為核心驅動力,依託多年積累形成的小分子藥物CDMO業務技術、質量控制及運營管理體系等多重優勢,加速拓展至生物藥CDMO業務等戰略新興板塊。

此次公司在上海奉賢投資建設生物藥CDMO研發及商業化生產基地,將藉助上海金山生物大分子研發中心的技術積累和人才優勢,進一步完善生物藥CDMO服務平台的搭建工作,通過建設國際化質量體系、積極拓展海外訂單、強化頭部客户帶動力、保障訂單交付能力以提升擴展生物藥CDMO服務能力和品牌效應,加速拓展以抗體偶聯藥物(ADC)、新型抗體藥物為代表的生物藥CDMO市場戰略新業務佈局,更多的參與及分享海內外生物藥迅速發展所催生的市場空間。該項目的建設符合公司整體做強小分子CDMO業務,加速戰略新興業務快速發展的“雙輪驅動”戰略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account